Pharvaris N.V. (PHVS)
NASDAQ: PHVS · Real-Time Price · USD
20.03
+0.15 (0.75%)
At close: Aug 1, 2025, 4:00 PM
20.00
-0.03 (-0.15%)
After-hours: Aug 1, 2025, 4:10 PM EDT
Company Description
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases.
The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant.
Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Pharvaris N.V.
| Country | Switzerland |
| Founded | 2015 |
| IPO Date | Feb 5, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 108 |
| CEO | Berndt Axel Modig |
Contact Details
Address: Grafenauweg 8 Zug, 6300 Switzerland | |
| Phone | 31 712036410 |
| Website | pharvaris.com |
Stock Details
| Ticker Symbol | PHVS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| IPO Price | $20.00 |
| CIK Code | 0001830487 |
| CUSIP Number | N69605108 |
| ISIN Number | NL00150005Y4 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Berndt Axel Edvard Modig CPA, M.B.A. | Co-Founder, Chief Executive Officer and Executive Director |
| David W. Nassif J.D. | Chief Financial Officer, Chief Legal Officer and Corporate Secretary |
| Anna Nijdam M.Sc., R.A. | Head of Strategic Finance and Principal Accounting Officer |
| Dr. Stefan Abele Ph.D. | Chief Technology Operations Officer |
| Annick Deschoolmeester | Chief Human Resources Officer |
| Dr. Peng Lu M.D., Ph.D. | Chief Medical Officer |
| Dr. Anne A. Lesage Ph.D. | Chief Early Development Officer |
| Wim Souverijns Ph.D. | Chief Commercial Officer |
| Maryann Cimino | Director of Corporate Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 24, 2025 | 6-K | Report of foreign issuer |
| Jul 24, 2025 | 424B5 | Filing |
| Jul 23, 2025 | FWP | Free Writing Prospectus |
| Jul 22, 2025 | 424B5 | Filing |
| Jul 14, 2025 | 144 | Filing |
| Jul 11, 2025 | 144 | Filing |
| Jul 10, 2025 | 6-K | Report of foreign issuer |
| Jun 27, 2025 | 6-K | Report of foreign issuer |
| Jun 10, 2025 | 6-K | Report of foreign issuer |
| May 13, 2025 | 6-K | Report of foreign issuer |